Komaki R, Cox J D, Hartz A, Wilson J F, Greenberg M
Am J Clin Oncol. 1984 Dec;7(6):661-8. doi: 10.1097/00000421-198412000-00013.
From 1965-1980, 80 patients with adenocarcinoma of the endometrium, FIGO-AJC Stage I, Grade 3 and Stage II received preoperative radiation therapy. Thirty-three patients had Stage I, Grade 3 and 47 had Stage II. All patients were treated with preoperative radiation therapy (intracavitary application, external pelvic irradiation or both) followed by total abdominal hysterectomy and bilateral salpingo-oophorectomy. They were followed from 3-18 years (median, 6.2 years) after the completion of treatment and none was lost to follow-up. Overall 5-year actuarial disease-free survival was 75%. Preoperative external whole pelvic plus intracavitary irradiation gave the best 5-year survival of 83%; there were no failures after 20 months. In comparison to this group, survival for the intracavitary alone group was 64% at 5 years and 54% at 8 years. The 5-year survival of Stage II was 81% compared to 66% of the Stage I, Grade 3 group. Prognostic variables were analyzed and showed that the residual tumor in the specimen at the time of surgery after the preoperative irradiation was significantly correlated to a worse prognosis: patients who were found to have no residual tumor had a 5-year survival rate of 96% compared to 65% of those who were found to have residual tumor (p less than 0.01). Age, stage, methods of preoperative irradiation, dose of external pelvic irradiation or intracavitary application were not statistically significant prognostic factors. The grade of the tumor was suggestive as a prognostic variable. The most common failure site was the para-aortic lymph nodes independent of treatment methods and stage. Four patients developed complications possibly related to the radiation therapy. Our study suggests that preoperative external and intracavitary irradiation reduces the frequency of residual microscopic carcinoma and improves survival for patients with Stage I, Grade 3 and Stage II carcinoma of the endometrium.
1965年至1980年期间,80例子宫内膜腺癌患者(国际妇产科联盟-美国癌症联合委员会分期为I期3级和II期)接受了术前放射治疗。其中33例为I期3级,47例为II期。所有患者均接受术前放射治疗(腔内照射、盆腔外照射或两者联合),随后行全腹子宫切除术及双侧输卵管卵巢切除术。治疗结束后对他们进行了3至18年的随访(中位随访时间为6.2年),无一例失访。总体5年无病生存率为75%。术前盆腔外全照射加腔内照射的5年生存率最高,为83%;20个月后无复发。与该组相比,单纯腔内照射组5年生存率为64%,8年生存率为54%。II期患者的5年生存率为81%,而I期3级组为66%。对预后变量进行分析发现,术前放疗后手术标本中的残留肿瘤与较差的预后显著相关:术中未发现残留肿瘤的患者5年生存率为96%,而发现有残留肿瘤的患者为65%(p<0.01)。年龄、分期、术前放疗方法、盆腔外照射剂量或腔内照射剂量均不是具有统计学意义的预后因素。肿瘤分级提示为一个预后变量。最常见的复发部位是主动脉旁淋巴结,与治疗方法和分期无关。4例患者出现了可能与放疗相关的并发症。我们的研究表明,术前盆腔外照射和腔内照射可降低微小残留癌的发生率,并提高子宫内膜I期3级和II期癌患者的生存率。